Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine |
| |
摘 要: |
|
关 键 词: | 免疫小鼠 疫苗 流感 病毒 分裂 单价 安全评价 灵长类动物 |
收稿时间: | 2009 Sep 16 |
Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine |
| |
Authors: | Penghui Yang Li Xing Chong Tang Weihong Jia Zhongpeng Zhao Kun Liu Xiao Gao Xiliang Wang |
| |
Institution: | Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China |
| |
Abstract: | The novel influenza A (H1N1) 2009 virus has emerged to cause the first pandemic of the twenty-first century. Disease outbreaks caused by the influenza A (H1N1) virus have prompted concerns about the potential for a pandemic and have driven the development of vaccines against this subtype of influenza A. In this study, we developed a monovalent influenza A (H1N1) split vaccine and evaluated its effects in BALB/c mice. Mice were immunized subcutaneously with 2 doses of the vaccine containing hemagglutinin (HA) alone or HA plus an aluminum hydroxide (Al(OH)3) adjuvant. Immunization with varying doses of HA (3.75, 7.5, 15, 30, 45 or 60 µg) was performed to induce the production of neutralizing antibodies. The vaccine elicited strong hemagglutination inhibition (HI) and microneutralization, and addition of the adjuvant augmented the antibody response. A preliminary safety evaluation showed that the vaccine was not toxic at large doses (0.5 ml containing 60 µg HA+600 µg Al(OH)3 or 60 µg HA). Moreover, the vaccine was found to be safe at a dose of 120 µg HA+1200 µg Al(OH)3 or 120 µg HA in 1.0 ml in rats. In conclusion, the present study provides support for the clinical evaluation of influenza A (H1N1) vaccination as a public health intervention to mitigate a possible pandemic. Additionally, our findings support the further evaluation of the vaccine used in this study in primates or humans. |
| |
Keywords: | BALB/c mice influenza influenza A (H1N1) split vaccine |
本文献已被 维普 等数据库收录! |
|